Skip to main content

Table 2 Characteristics of pDILI Type 1 cases (BTS/ATS criteria) and controls

From: Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK

Characteristic

 

Controls

DILI cases

 
  

Median (IQR)

Median (IQR)

P-value†

Baseline ALT (IU/L)

 

19 (14–29), n = 185

24 (17–32), n = 77

0.03

Baseline ALP (IU/L)

 

86 (71–102), n = 187

98 (75–135), n = 77

0.03

Baseline bilirubin (umol/L)

8 (5–10), n = 185

8 (6–12), n = 77

0.28

Weight (kg)

 

61.2 (54.5–69.6), n = 178

53.9 (48.0–65.0), n = 74

0.001

Rifampicin dose per kg

(if given)

9.68 (8.62–10.7), n = 178

9.98 (9.00–11.1), n = 74

0.17

Isoniazid dose per kg

(if given)

4.85 (4.31–5.45), n = 178

5.57 (4.62–6.25), n = 74

<0.001

Pyrazinamide dose per kg

(if given)

24.4 (21.4–27.5), n = 178

25.8 (22.7–29.8), n = 74

0.05

Moxifloxacin dose per kg

(if given)

6.15 (5.71–7.04), n = 21

7.67 (5.71–8.00), n = 10

0.20

  

% (fraction)

% (fraction)

 

HIV positive

 

2.2 (4/185)

7.3 (5/69)

0.06

HCV positive

 

1.7 (3/179)

1.4 (1/73)

1.00

HBV positive

 

2.2 (4/180)

0.0 (0/74)

0.33

Alcohol consumptiona

Nil

93.3 (167/179)

71.4 (40/56)

<0.001

 

Any

6.7 (12/179)

28.6 (16/56)

 

Chronic Liver Disease

 

2.2 (4/186)

3.9 (3/77)

0.42

  1. † P-values from Kruskal-Wallis test (medians), Fisher’s exact test (proportions)
  2. a Most patients drank no alcohol and only 1 patient (male) drank in excess of 21 units/week; given the small number of high alcohol intake, this was analysed as no intake versus any intake of alcohol